Physician profile
Jamie Rup
NPI 1205468543
$2,823.57
in general payments reported to CMS, 2019-2025
30 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $760 · 2022: $708 · 2023: $306 · 2024: $522 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $405.03 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $356.08 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $313.26 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $170.40 | 2022-2025 | |
| Abbvie INC. | $148.06 | 2021-2024 | |
| Amgen INC. | $142.31 | 2021-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $127.74 | 2021-2025 | |
| Axsome Therapeutics, INC. | $124.97 | 2022-2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.89 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $91.86 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $89.22 | 2021-2025 | Enflonsia, Capvaxive, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $81.61 | 2021 | |
| Astellas Pharma US INC | $65.62 | 2023-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $64.61 | 2021-2023 | Gvoke Hypopen |
| Avanir Pharmaceuticals, INC. | $60.13 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $56.87 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $50.06 | 2021-2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $45.04 | 2022 | |
| Dynavax Technologies Corporation | $43.61 | 2023-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $38.48 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $37.93 | 2021-2022 | |
| Dexcom, INC. | $36.80 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.32 | 2021 | |
| Acadia Pharmaceuticals INC | $28.54 | 2022 | |
| Vanda Pharmaceuticals INC. | $23.95 | 2025 | Fanapt |
| Sanofi-Aventis U.S. LLC | $20.23 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.62 | 2022 | |
| Antares Pharma, INC. | $15.99 | 2024 | Xyosted |
| Inspire Medical Systems, INC. | $15.42 | 2025 | Inspire |
| Eisai INC. | $14.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Rup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.